

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 331 240
A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89200437.5

(51) Int. Cl.⁵: **C07D 309/30, C07F 7/18,
A61K 31/365**

(22) Date of filing: 22.02.89

(30) Priority: 29.02.88 US 161529

(43) Date of publication of application:
06.09.89 Bulletin 89/36

(84) Designated Contracting States:
CH DE FR GB IT LI NL

(98) Date of deferred publication of the search report:
16.05.90 Bulletin 90/20

(71) Applicant: **MERCK & CO. INC.**
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0900(US)

(72) Inventor: **Lee, Ta Jyh**
1921 Supplee Road
Lansdale Pennsylvania 19446(US)
Inventor: **Hoffman, William F.**
740 Weikel Road
Lansdale Pennsylvania 19446(US)

(74) Representative: **Hesketh, Alan, Dr.**
European Patent Department Merck & Co.,
Inc. Terlings Park Eastwick Road
Harlow Essex, CM20 2QR(GB)

(54) **Intermediates and processes for beta 6-hydroxymethyl HMG-COA.**

(57) This invention discloses intermediates and a process for the preparation of 6-desmethyl-6- β -hydroxymethyl derivatives of lovastatin and analogs thereof at the 8-acyl side chain.

EP 0 331 240 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 20 0437

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP-A-0 245 990 (MERCK) * Page 13; claims * -----	1	C 07 D 309/30 C 07 F 7/18 A 61 K 31/365
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 D 309/00 C 07 F 7/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 10-02-1990	Examiner FRANCOIS J.C.L.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P0401)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 331 240
A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89200437.5

(51) Int. Cl.⁴: **C07D 309/30 , C07F 7/18 ,
A61K 31/365**

(22) Date of filing: 22.02.89

(30) Priority: 29.02.88 US 161529

(43) Date of publication of application:
06.09.89 Bulletin 89/36

(84) Designated Contracting States:
CH DE FR GB IT LI NL

(71) Applicant: **MERCK & CO. INC.**
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0900(US)

(72) Inventor: **Lee, Ta Jyh**
1921 Supplee Road
Lansdale Pennsylvania 19446(US)
Inventor: **Hoffman, William F.**
740 Weikel Road
Lansdale Pennsylvania 19446(US)

(74) Representative: **Hesketh, Alan, Dr.**
European Patent Department Merck & Co.,
Inc. Terlings Park Eastwick Road
Harlow Essex, CM20 2QR(GB)

(54) **Intermediates and processes for beta 6-hydroxymethyl HMG-COA.**

(57) This invention discloses intermediates and a process for the preparation of 6-desmethyl-6- β -hydroxymethyl derivatives of lovastatin and analogs thereof at the 8-acyl side chain.

EP 0 331 240 A2


INTERMEDIATES AND PROCESSES FOR BETA 6-HYDROXYMETHYL HMG-CoA REDUCTASE INHIBITORS

BACKGROUND OF THE INVENTION

Hypercholesterolemia is known to be one of the prime risk factors for ischemic cardiovascular disease, such as arteriosclerosis. Bile acid sequestrants have been used to treat this condition; they seem to be moderately effective but they must be consumed in large quantities, i.e. several grams at a time and they are not very palatable.

MEVACOR® (lovastatin), now commercially available, is one of a group of very active antihypercholesterolemic agents that function by limiting cholesterol biosynthesis by inhibiting the enzyme, HMG-CoA reductase. In addition to the natural fermentation products, mevastatin and lovastatin, they are a variety of semi-synthetic and totally synthetic analogs thereof.


The naturally occurring compounds and their semi-synthetic analogs have the following general structural formulae:




wherein:

R³ is hydrogen, C₁₋₅ alkyl or C₁₋₅ alkyl substituted with a member of the group consisting of phenyl, dimethylamino, or acetylamino; and


R² is




wherein Q is




R² is hydrogen or methyl; and a, b, c, and d represent single bonds, one of a, b, c or d represents a double bond, or both a and c or both b and d represent double bonds provided that when a is a double bond,



U.S. Patent 4,517,373 discloses semi-synthetic hydroxy containing compounds represented by the above general formula wherein R* is




15 U.S. Patent 4,537,859 and U.S. Patent 4,448,979 also disclose semi-synthetic hydroxy-containing compounds represented by the above general formula wherein R* is




These compounds are prepared by the action of certain microorganisms on the corresponding non-hydroxylated substrates. One such organism described in U.S. 4,537,859 is of the genus *Nocardia*.


30 U.S. Patent 4,376,863 discloses a fermentation product, isolated after cultivation of a microorganism belonging to the genus *Aspergillus*, which has a hydroxy containing butyryloxy side chain and is represented by the above general formula wherein R* is



45 Japanese unexamined patent application J59-122,483-A discloses a semi-synthetic hydroxy-containing compound represented by the above general formula wherein R* is



EP 251625 discloses 6-substituted compounds of the above general formula wherein R* is



wherein R is CH_2OH , $\text{CH}_2\text{O}-\text{C}(=\text{O})-\text{R}^4$, CO_2R^7 or $\text{C}(=\text{O})-\text{NR}^8\text{R}^9$; and R^1 , R^4 , R^7 , R^8 and R^9 are broadly defined organic moieties.

The compounds of the above-mentioned EP 251625 wherein a and c are double bonds were prepared by a microbiological conversion of lovastatin or an analog thereof with a 6-methyl substituent. Compounds where one of a, b or c all represent a double bond or a, b, c represent single bonds were prepared by a synthetic sequence from the 8-hydroxy-6-methyl derivative.

EP 88202761 discloses intermediates and processes for preparing 6-desmethyl-6-carboxy derivatives of lovastatin and 8-acyl analogs wherein the 6-carboxy moiety has the alpha stereochemical configuration.

Copending European Patent Applications, of even date herewith, claiming priorities from US Serial Nos. 161530 filed 29th February 1988 and 161579 filed 29th February 1988 respectively, disclose intermediates and processes for preparing 6-desmethyl-6-hydroxy-methyl derivatives of lovastatin and 8-acyl analogs, wherein the 6-hydroxymethyl moiety has the alpha stereochemical configuration.


The literature discloses a reaction known as the Barton Reaction by which a hydrogen on the γ carbon to a COH group can be abstracted to afford a carbon radical which can be oxidized. (See Hesse Adv. Free-Radical Chem. 3, 83-137 (1969); Barton, Pure Appl. Chem. 16, 1-15 (1968); Arthar, Adv. Photochem. 2, 263-304 (1964).

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to novel intermediates, and a novel process for their preparation, where said intermediates are useful in a novel preparation of 6-desmethyl-6- β -hydroxymethyl (I) derivatives of lovastatin and 8-acyl analogs thereof wherein the 6-hydroxymethyl moiety has the beta stereochemical configuration. Said 6-hydroxymethyl derivatives of lovastatin and analogs thereof are useful in treating hypercholesterolemia and are disclosed in EP 251625.


The overall process of this invention for preparing the 6-desmethyl-6- β -hydroxymethyl (I) derivatives of lovastatin is shown in scheme 1.

SCHEME 1



The intermediates (8) of the present invention are prepared in a novel process (i) which comprises:

(A) treating the starting material (1)



wherein:

n is 0 to 3;

R₁ and R₂ independently are hydrogen, C₁₋₅ alkyl, or R₁ and R₂ together with the carbon atom to which they are attached form a carbocyclic ring of 3 to 8 carbon atoms;

R₃ and R₄ are independently hydrogen, C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkylthio, phenyl, phenylthio or substituted phenyl in which the substituents are V and W and when n is 2 to 3, each of the R₃s and R₄s are independently hydrogen, C₁₋₃ alkyl, C₃₋₇ cycloalkyl or only one of the R₃s or R₄s on the chain of carbons is phenyl or substituted phenyl;

R₅ is hydrogen, tosylate, OT, C₁₋₅ alkyl or C₁₋₅alkyl substituted with tosylate or OT, C₃₋₇ cycloalkyl or C₃₋₇ cycloalkyl substituted with C₁₋₃ alkyl, tosylate or OT; C₂₋₅ alkenyl, phenyl or substituted phenyl in which the substituents are V and W, or R₅ is a group selected from:

a) C₁₋₅-alkanoyloxy- C₁₋₄-alkyl,


b)

R₅-O-C(=O)-(CH₂)_m in which m is 0 to 3 and R₆ is C₁₋₅ alkyl;

c) R₇R₈N-C(=O)-(CH₂)_m

in which R₇ and R₈ are independently C₁₋₅ alkyl or R₇ and R₈ together with the nitrogen atom to which they are attached form a heterocycle selected from piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl or thiomorpholinyl;


d)



in which q is 0 to 2 and R₉ is C₁₋₅ alkyl or phenyl or substituted phenyl in which the substituents are V and W;


V and W independently are hydrogen, halogen, hydroxy, trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkyloxy and TO-C₁₋₃ alkyl;

with a hydroxyl protecting compound such as tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, trimethylsilyl chloride, triethylsilyl chloride, triisopropylsilyl chloride or dihydropyran to yield a compound (2) wherein




15 T is a hydroxyl protecting group such as tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl;


(b) contacting the compound (2) with a halogenating agent such as a phenylselenenyl halide or phenylsulfinyl chloride in an inert solvent at about - 80° C then treating the product with an oxidizing agent
20 such as hydrogen peroxide or a peroxyacid in an ethereal solvent at ambient temperature to yield a compound (3) wherein X = Cl or Br;




(c) treating the compound (3) with a trialkyl or triaryltin hydride such as tri(n-butyl)tin hydride and a radical initiator such as azobisisobutyronitrile to yield a compound (4);




(d) contacting the compound (4) with nitrosyl chloride and base, followed by irradiation with light to yield a compound (5);




(e) treating compound (5) with an acidic mixture in a polar solvent such as $\text{HF}:\text{CH}_3\text{CN}$ at about -15°C to afford compound (6)




(f) heating the compound (6) in a protic solvent such as isopropanol to afford compound (7)




(g) treating compound (7) with an aqueous paraformaldehyde solution in the presence of an acid catalyst to yield compound (8);



- Intermediates (8) are used to form intermediates (9) in a novel process (ii) which comprises:
 (h) contacting compound (8) with aluminum isopropoxide and aluminum oxide in an alcoholic solvent to yield compound (9):




- Products (I) are formed from intermediates (9) in a novel process (iii) which comprises:
 (i) contacting intermediate (9) with an acid in a polar solvent to yield compound (I):



wherein R_5' is identical to R_5 except that any OT protecting group is hydrolyzed to OH.

- It should be understood that the alkyl, alkylthio, alkenyl, and alkanoyl groups of this invention may either be in a straight chain or branched configuration.
 One embodiment of this invention is the compounds of formula (8):



wherein n , R_1 , R_2 , R_3 , R_4 , R_5 and T are defined above.

In one class of this embodiment are the compounds of formula (3) wherein:

R_1 is methyl;

R_2 is hydrogen or methyl;

R_3 and R_4 are independently hydrogen or C_{1-3} alkyl.

In a subclass:

R_5 is hydrogen, tosylate, OT, C_{1-5} alkyl, phenyl or substituted phenyl in which the substituents are V and W;

T is *tert*-butyldimethylsilyl.


Exemplifying this subclass are compounds (8) wherein:

(1) n is 0, R_2 is methyl, R_5 is ethyl;

(2) n is 0, R_2 is hydrogen, R_5 is ethyl.

A second embodiment of this invention is the process for the preparation of intermediates (8) from starting material (1). This process consists of (a) contacting compound (1) with a hydroxyl protecting compound; (b) treatment with a halogenating agent in an inert solvent followed by treatment with an oxidizing agent in an ethereal solvent; (c) treatment with a trialkyl or triaryl tin hydride and a radical initiator; (d) contact with nitrosyl chloride followed by irradiation with light; (e) treatment with $HF \cdot CH_3CN$; (f) contact with isopropanol; (g) treatment with paraformaldehyde.

A third embodiment of the instant invention is the compounds of formula (9):



wherein n , R_1 , R_2 , R_3 , R_4 , R_5 and T have the same values as in the general embodiment of compounds (8) formula (9) wherein:

R_1 is methyl;

R_2 is hydrogen or methyl;

R_3 and R_4 are independently hydrogen or C_{1-3} alkyl.

In a subclass:

R_5 is hydrogen, tosylate, OT, C_{1-5} alkyl, phenyl or substituted phenyl in which the substituents are V and W;

T is *tert*-butyldimethylsilyl.

Exemplifying this subclass are compounds (9) wherein:

- (1) n is 0, R₂ is methyl, R₅ is ethyl;
- (2) n is 0, R₂ is hydrogen, R₅ is ethyl.

A fourth embodiment of the present invention is the process for the preparation of intermediates (9) from intermediates (8). This process consists in contacting a compound of formula (8) with aluminum isopropoxide and aluminum oxide.

Starting material (1) is treated with a reagent suitable for protecting the alcohol group at the lactone 4-position. Examples of suitable reagents are trialkylsilyl chlorides, dialkylarylsilyl chlorides and dihydropyran.

The diene (2) of step (B) is treated with a halogenating agent such as phenylselenenyl chloride or bromide or phenylsulfinyl chloride, preferably phenylselenenyl chloride, in an approximately equimolar ratio in an inert solvent at about -80 °C, for approximately 20 minutes; illustrative of such inert solvents are methylene chloride, ether and the like. After a standard workup the product residue is dissolved in an ethereal solvent, chilled to about 0 °C and oxidized with an agent such as 30% hydrogen peroxide or a peroxy acid such as peroxybenzoic acid to yield a halohydrin analog (3).

Intermediate (3) is treated with a halide reducing agent such as a trialkyltin hydride or a triaryltin hydride, preferably tri-n-butyltin hydride and a radical initiator such as azobisisobutyronitrile (AIBN) in an inert solvent such as benzene at a temperature between 70 °C and 100 °C preferably about 90 °C for 0.5 to 5 hours preferably 2 hours.

Compound (4) is treated with nitrosyl chloride at a temperature between -10 and 10 °C, preferably 0 °C for several minutes in a basic solvent until TLC analysis of an aliquot showed the reaction to be complete. Illustrative of such basic solvents are pyridine and quinoline and the like. In a second step the irradiation is conducted using light of wavelength greater than 320 Å. One source of the irradiation is a medium pressure mercury lamp, at a temperature between 0 ° and 30 °C, preferably at about 20 °C, for a period of from 0.5 to 5 hours, most preferably about 0.7 hours at 20 °C, in an inert solvent such as benzene, pyridine, hexane or the like, or a mixture of inert solvents.

Compound (5) is treated with an aqueous acidic mixture such as approximately 48% HF or perchloric acid in a polar solvent such as acetonitrile or aqueous acetone at a temperature between -20 °C and 10 °C, preferably 48% HF/CH₃CN at about -15 °C.

The rearrangement of a compound of formula (6) to a compound of formula (7) is conducted at a temperature between 60 °C and 100 °C, preferably at about 95 °C for a period of 0.5 to 10 hours, most preferably for 2 hours at about 95 °C, in a protic solvent and an amine base. Illustrative of such protic solvents are alcohols such as isopropanol or 2-butanol and the like. Examples of amine bases are pyridine, triethylamine, quinoline, and the like.

The conversion of an oxime (7) to an aldehyde (8) is conducted using an approximately 40% aqueous paraformaldehyde solution and a carboxylic acid such as acetic acid.

The aldehyde (8) is converted into a hydroxymethyl alcohol of beta stereochemical configuration by treatment with aluminum isopropoxide and aluminum oxide in an alcohol at a temperature between 80 ° to 100 °C for 80 hours, preferably about 90-95 °C for approximately 60 hours. Approximately one third of the total amount of aluminum isopropoxide and aluminum oxide is added initially and the remainder after about 22 hours. The total mole ratio of aluminum isopropoxide to aldehyde (8) is 1.5:1. Examples of appropriate alcohols are isopropanol and 2-butanol.

Intermediate (9) is dehydrated and the silyl ether or tetrahydropyranyl group removed by treatment with an aqueous acid in a polar solvent, preferably hydrofluoric acid in acetonitrile, most preferably 48% hydrofluoric acid in acetonitrile, at 0 ° to 60 °C, preferably 55-60 °C for about 1 hour.

Starting compounds (1) wherein the acyl side chain is other than 2-methylbutyryloxy are prepared from lovastatin by hydrolysis of the 8-acyl side chain, following the procedure in U.S. Patent 4,444,784, followed by acylation with an appropriate alkanoyl chloride in the presence of lithium bromide and dimethylaminopyridine in pyridine using the procedure in EP 287340. Alternatively, the acylation is conducted with an alkanoyl chloride or an alkanoyl acid under standard reaction conditions. The alkanoyl chloride can be formed by standard chemical transformations such as substitution with an alkyl moiety or other appropriate electrophile at an acidic C-H site on an available starting material.

The following examples illustrate the present invention and as such are not to be considered as limiting the invention set forth in the claims appended hereto.

EXAMPLE 1

Preparation of 6(R)-[2-[6(S)-hydroxymethyl-8(S)-(2,2-Dimethylbutyryloxy)-2(S)-methyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

- (a) 6(R)-[2-[8(S)-(2,2-Dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(t-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (2)

Tert-Butyldimethylsilyl chloride (8 g, 52 mmol) was added to a stirred solution of 6(R)-[2-[8(S)-(2,2-Dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one (20 g, 48 mmol) and imidazole (6.8 g, 0.1 mol) in DMF (150 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 5 minutes, then warmed to room temperature and stirred for 5 hours. TLC analysis of an aliquot indicated that the reaction was complete. The reaction mixture was poured into cold water and extracted with ether. The ethereal extract was washed with dilute hydrochloric acid, water and 5% sodium bicarbonate solution. After drying over MgSO₄, the organic extract was filtered and the filtrate was concentrated in vacuo to afford the desired product as a colorless, viscous oil: NMR (CDCl₃) δ 0.84 (3H, t, J = 7Hz), 0.89 (3H, d, J = 7Hz), 0.90 (9H, s), 1.09 (3H, d, J = 7Hz), 1.11 (3H, s), 1.12 (3H, s), 4.30 (H, m), 4.60 (H, m), 5.33 (H, m), 5.51 (H, m), 5.77 (H, d of d, J = 10, 6Hz), 5.98 (H, d, H = 10Hz).

- (b) 6(R)-[2-[5(S)-Chloro-4a(S)-hydroxy-8(S)-(2,2-dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,4a,5, 6,7,8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (3)

A solution of phenylselenenyl chloride (10 g, 52 mmol) in methylene chloride (50 mL) was added dropwise to a stirred solution of compound 2' (25.2 g, 48 mmol) in methylene chloride (350 mL) cooled in a dry ice/ipropanol bath (-78 °C). The resulting mixture was stirred at -78 °C for 20 minutes, poured into cold water (300 mL) and extracted with ether twice (400 mL, then 150 mL). The combined extracts were dried (MgSO₄), filtered and concentrated to afford an oily residue which was dissolved in tetrahydrofuran (300 mL). This solution was chilled in an ice bath (0 °C), and 30% hydrogen peroxide (15 mL) was added. The resulting mixture was stirred at 0 °C for 5 minutes, then warmed to room temperature and stirring continued for 1 hour. The reaction mixture was poured into cold water and extracted with chloroform three times (400 mL, then 2 x 100 mL). The combined extracts were dried (MgSO₄), filtered and concentrated to yield a residue which was purified by flash chromatography on a silica gel column. Elution with hexane:ethyl acetate (5:1/v:v) removed the impurities. Further elution with hexane:ethyl acetate (4:1/v:v) provided the title compound as a pale yellow gum which later solidified on standing: mp 117-8 °C, NMR (CDCl₃) δ 0.075 (3H, s), 0.08 (3H, s), 0.85 (3H, t, J = 7Hz), 0.88 (9H, s), 0.89 (3H, d, J = 7Hz), 1.15 (3H, s), 1.16 (3H, s), 1.32 (3H, d, J = 7Hz), 1.58 (2H, q, J = 7Hz), 3.39 (H, s), 4.05 (H, bs), 4.30 (H, m), 4.60 (H, m), 5.32 (H, m), 5.59 (H, d, J = 11Hz), 5.79 (H, d of d, J = 11, 6Hz).

Anal. Calcd. for C ₃₁ H ₅₃ ClO ₆ Si:	C,	63.61;	H,	9.13.
Found:	C,	63.80;	H,	9.04.

- (c) 6(R)-[2-[4a(S)-hydroxy-8(S)-2,2-dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,4a,5,6,7,8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (4)

Tributyltin hydride (7.06 mL, 26.25 mmol) and azobisisobutyronitrile (AIBN) (0.82 g, 5.0 mmol) were added to a magnetically stirred solution of chlorohydrin 3' (8.78 g, mmol) in benzene (100 mL). The resulting solution was refluxed for 2 hours, cooled and concentrated in vacuo to a viscous yellow oil which was stirred with pet ether (200 mL) at -15 °C (ice/acetone bath) to provide 4' as a fluffy, colorless solid (6.9 g, mp 97-9 °C). The filtrate was extracted with CH₃CN (4 x 50 mL) to remove all of the product contained in the pet ether. The CH₃CN extracts were combined and concentrated to a colorless oil which was purified by flash chromatography on a silica gel column. Elution with ethyl acetone/hexane (1:3/v:v) gave a colorless solid (1.0 g) which was stirred in pet ether (25 mL) at 0 °C to remove some tin residues. The mixture was filtered to provide the product 4' as a colorless solid. M.P. 103-4 °C, nmr (CDCl₃) δ 0.07 (3H, s), 0.08 (3H, s), 0.88 (9H, s), 1.15 (3H, s), 1.16 (3H, s), 1.20 (3H, d, J = 7Hz), 2.78 (H, s), 4.28 (H, m), 4.58 (H, m), 5.30 (H, m), 5.58 (H, d, J = 10Hz), 5.67 (H, dd, J = 10, 5Hz).

Anal. Calcd. for C ₃₁ H ₅₄ O ₆ Si:	C,	67.59;	H,	9.88.
Found:	C,	67.20;	H,	9.99.

5

(d) 6(R)-[2-[4a(S)-hydroxy-8(S)-(2,2-dimethylbutyryloxy)-2(S)-methyl-6(R)-nitrosylmethyl-1,2,4a,5,6, 7,8,8a-(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (5)

10 Nitrosyl chloride gas was bubbled through a stirred solution of compound 4' (1.25 g, 2.27 mmol) in pyridine (25 ml) at 0 °C for several minutes until the reaction mixture became a dark brown color. An aliquot was taken and partitioned between ether and water. If TLC analysis¹ of the ether layer indicated the completion of the reaction, the reaction mixture was poured into an ice/water mixture (50 ml) and extracted with benzene (50 ml). The aqueous phase was separated and extracted with benzene (25 ml). The
15 combined extracts were dried and filtered.

⁽¹⁾When eluted with hexane: ethyl acetate (4:1/v:v), the R_f values of compound 4' and its corresponding nitrate are 0.2 and 0.32 respectively.

The filtrate was diluted with benzene to a volume of 410 ml and transferred to a photoreactor. It was deoxygenated by bubbling nitrogen gas through the solution for 10 minutes. Then, it was irradiated (450
20 Watt Hanovia medium pressure mercury lamp, pyrex sleeve) at room temperature for 0.5 hour while nitrogen gas continued to bubble through the solution. The photolyzed solution was transferred to a R-B flask, concentrated on a rotary evaporator followed by evaporation under high vacuum. The residue was then purified by flash chromatography on a silica gel column. Impurities were removed by elution with hexane:ethyl acetate (3:1/v:v to 1.5:1/v:v). Further elution with hexane:ethyl acetate (1:1/v:v) provided 6(R)-
25 [2-[4a(S)-hydroxy-8(S)-(2,2-dimethylbutyryloxy)-2(S)-methyl-6(R)-hydroxyiminomethyl-1,2,4a,5,6,7,8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one and the titled compound 5: NMR (CDCl₃) δ 0.075 (3H, s), 0.085 (3H, s), 0.88 (9H, s), 1.19 (3H, s), 1.20 (3H, s), 2.68 (H, s), 4.29 (H, m), 4.33 (H, d of d, J = 11, 7Hz), 4.59 (H, m), 4.97 (H, d of d, J = 11, 7Hz), 5.25 (H, m), 5.55 (H, d, J = 10Hz), 5.67 (H, d of d, J = 10, 6Hz).

30

(e) 6(R)-[2-[3(S)-hydroxy-8(S)-(2,2-dimethylbutyryloxy)-2(R)-methyl-6(S)-nitrosylmethyl-1,2,3,5,6,7, 8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (6)

35 Cold (-20 °C) 48% aq. HF/CH₃CN (1:19/v:v, 10 ml) was added to a magnetically stirred acetonitrile solution (20 ml) of the nitrosomethyl compound 5' (750 mg, 1.29 mmol) cooled to -15 °C (ice-acetone bath). After 15 minutes the reaction was quenched by the addition of saturated NaHCO₃ solution (20 ml) and the resulting mixture was poured into ether (200 ml). The ether was washed with brine (2 x 25 ml) and dried over MgSO₄. Filtration and evaporation provided the title compound as a viscous pale yellow oil which was
40 purified by flash chromatography on a silica gel column. Elution with acetone/methylene chloride (1:5.6/v:v) gave compound 6' as an oil. NMR (CDCl₃) δ 0.081 (6H, s), 0.76 (3H, d, J = 7Hz), 0.83 (3H, t, J = 7Hz), 0.89 (9H, s), 1.188 (3H, s), 1.193 (3H, s), 3.87 (2H, m), 4.30 (H, m), 4.61 (H, m), 4.79 (H, m), 5.40 (H, m), 5.74 (H, m).

45

(f) 6(R)-[2-[3(S)-hydroxy-6(S)-hydroxyiminomethyl-8(S)-(2,2-dimethylbutyryloxy)-2(R)-methyl-1,2,3,5, 6,7,8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (7)

50 A magnetically stirred isopropanol solution (50 ml) containing the nitrosomethyl compound 6' (470 mg, 0.81 mmol) and pyridine (195 μl, 2.43 mmol) was heated at 95-100 °C (oil bath) for 2 hours. The solution was cooled and concentrated in vacuo to provide the oxime 7' as a beige colored foam. NMR (CDCl₃) δ 0.079 (6H, s), 0.88 (9H, s), 2.80 and 3.40 (H, both m), 3.86 (H, m), 4.29 (H, m), 4.60 (H, m), 5.40 (H, m), 5.79 (H, m), 6.85 and 7.54 (H, both d, J = 6Hz).

55

(g) 6(R)-[2-[6(S)-formyl-3(S)-hydroxy -8(S)-2,2-dimethylbutyryloxy)-2(R)-methyl-1,2,3,5,6,6,8,8a (S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (8)

A 40% aqueous paraformaldehyde solution (50 ml) and acetic acid (46 μ l, 0.81 mmol) were added to a solution of the oxime 7' (470 mg, 0.81 mmol) in acetone (50 ml) and the reaction mixture was stirred at ambient conditions overnight. The acetone was removed in vacuo at 25 °C and the aqueous residue was extracted with ether (2 x 100 ml). The ether extracts were combined, washed with brine (20 ml) and dried over MgSO₄. Filtration and evaporation in vacuo gave the crude aldehyde 8' which was purified by flash chromatography on silica gel. Elution with acetone/methylene chloride (1:9/v:v) provided the title compound as a colorless viscous oil. NMR (CDCl₃) δ 0.077 (3H, s), 0.080 (3H, s), 0.72 (3H, d, J = 7Hz), 0.81 (3H, t, J = 7Hz), 0.89 (9H, s), 1.08 (3H, s), 1.09 (3H, s), 2.91 (H, d, J = 14Hz), 3.85 (H, m), 4.29 (H, m), 4.60 (H, m), 5.39 (H, m), 5.87 (H, d, J = 5Hz), 9.64 (H, s).

(h) 6(R)-[2-[3(S)-hydroxy-6(R)-hydroxymethyl-8(S)-(2,2-dimethylbutyryloxy)-2(R)-methyl-1,2,3,5,6,7, 8,8a(S)-octahydronaphthyl-1(S)]ethyl]-4(R)-(t-butylidimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (9)

Aluminum isopropoxide (9.76 mg, 0.048 mmol) and aluminum oxide (activated, neutral, 50 mg), were added to an isopropanol solution (10 ml) of the aldehyde 8 (54 mg, 0.0956 mmol) and the reaction mixture was stirred at 90-95 °C (oil bath) for 58 hours. (After 22 hours more aluminum isopropoxide (19.5 mg, 0.0956 mmol) and aluminum oxide (100 mg) were added.) After cooling the reaction mixture was filtered and the filtrate concentrated in vacuo to give the alcohol 9' as a viscous oil which was purified by flash chromatography on a silica gel column. Elution with acetone/methylene chloride (1:4/v:v) gave the title compound as a colorless oil. NMR (CDCl₃) δ 0.078 (3H, s), 0.080 (3H, s), 0.74 (3H, d, J = 7Hz), 0.83 (3H, t, J = 7Hz), 0.89 (9H, s), 1.16 (6H, s), 3.45 (2H, m), 3.84 (H, m), 4.28 (H, m), 4.61 (H, m), 5.36 (H, m), 5.72 (H, d, J = 5Hz). Further elution with the same eluant gave the 6- α -hydroxymethyl isomer as a colorless oil. NMR (CDCl₃) δ 0.077 (3H, s), 0.081 (3H, s), 0.76 (3H, d, J = 7Hz), 0.84 (3H, t, J = 7Hz), 0.90 (9H, s), 1.18 (3H, s), 1.19 (3H, s), 3.49 (H, dd, J = 10, 6Hz), 3.70 (H, dd, J = 18Hz, 5Hz), 3.86 (H, m), 4.29 (H, m), 4.61 (H, m), 5.37 (H, m), 5.76 (H, d, J = 5Hz).

(i) 6(R)-[2-[6(S)-hydroxymethyl-8(S)-(2,2-dimethylbutyryloxy)-2(S)-methyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one (I)

A solution of 48% aqueous HF/CH₃CN (1:19/v:v, 5 ml) was added to a magnetically stirred acetonitrile solution (5 ml) of the compound 9' (46 mg, 0.081 mmol) and the reaction mixture heated at 60 °C (oil bath) for 1 hour. The solution was cooled to 0 °C and quenched by the addition of saturated NaHCO₃ solution (10 ml). The resulting mixture was poured into ether (50 ml) and the ether was washed with brine (2 x 10 ml) and dried over MgSO₄. Filtration and evaporation gave the title compound I' which was purified by flash chromatography on a silica gel column. Elution of the column with acetone/methylene chloride (1:2.3/v:v) gave the title compound. NMR (CDCl₃) δ 0.83 (3H, t, J = 7Hz), 0.90 (3H, d, J = 7Hz), 1.13 (6H, s), 3.54 (H, m), 3.64 (H, m), 4.36 (H, m), 4.63 (H, m), 5.37 (H, m), 5.51 (H, m), 5.79 (H, dd, J = 10, 6Hz), 6.00 (H, d, J = 10Hz).


Claims

1. A compound of structural formula (8):

5

10

15



wherein

20 n is 0 to 3;

R₁ and R₂ independently are hydrogen, C₁₋₅alkyl, or R₁ and R₂ together with the carbon atom to which they are attached form a carbocyclic ring of 3 to 8 carbon atoms;

R₃ and R₄ are independently hydrogen, C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkylthio, phenyl, phenylthio or substituted phenyl in which the substituents are V and W and when n is 2 to 3, each of the R₃s and R₄s are
25 independently hydrogen, C₁₋₃ alkyl, C₃₋₇ cycloalkyl or only one of the R₃s or R₄s on the chain of carbons is phenyl or substituted phenyl;

R₅ is hydrogen, tosylate, OT, C₁₋₅alkyl or C₁₋₅alkyl substituted with tosylate or OT, or C₃₋₇cycloalkyl or C₃₋₇cycloalkyl substituted with C₁₋₃alkyl, tosylate or OT, C₂₋₅ alkenyl, phenyl or substituted phenyl in which the substituents are V and W, or R₅ is a group selected from:

30 a) C₁₋₅-alkanoyloxy-C₁₋₅-alkyl,

b)

$$R_6-O-\overset{\overset{O}{\parallel}}{C}-(CH_2)_m$$
 in which m is 0 to 3 and R₆ is C₁₋₅ alkyl;


c)
$$R_7R_8N-\overset{\overset{O}{\parallel}}{C}-(CH_2)_m$$
 in which R₇

35

and R₈ are independently C₁₋₅ alkyl or R₇ and R₈ together with the nitrogen atom to which they are attached form a heterocycle selected from piperidiny, morpholinyl, pyrrolidinyl, piperazinyl or thiomorpholinyl;

d)

40



45

in which q is 0 to 2 and R₉ is C₁₋₅alkyl or phenyl or substituted phenyl in which the substituents are V and W;

V and W independently are hydrogen, halogen, hydroxy, trifluoromethyl, C₁₋₃alkyl, C₁₋₃ alkyloxy and TO-C₁₋₃alkyl;

50 T is tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl.

2. A compound of Claim 1 wherein:

R₁ is methyl;

R₂ is hydrogen or methyl;

55 each of the R₃'s and R₄'s are independently hydrogen or C₁₋₃alkyl.

3. A compound of Claim 2 wherein:

R_5 is hydrogen, tosylate, OT, C_{1-5} alkyl, phenyl or substituted phenyl in which the substituents are V and W;


T is tert-butyldimethylsilyl.

4. A compound of Claim 3 selected from the group wherein:

a) n is 0, R_2 is methyl, R_5 is ethyl;

b) n is 0, R_2 is hydrogen, R_5 is ethyl.

5. A compound of structural formula (9):



wherein:

n is 0 to 3;

R_1 and R_2 independently are hydrogen, C_{1-5} alkyl, or R_1 and R_2 together with the carbon atom to which they are attached form a carbocyclic ring of 3 to 8 carbon atoms;

R_3 and R_4 are independently hydrogen, C_{1-3} alkyl, C_{3-7} cycloalkyl, C_{1-3} alkylthio, phenyl, phenylthio or substituted phenyl in which the substituents are V and W and when n is 2 to 3, each of the R_3 s and R_4 s are independently hydrogen, C_{1-3} alkyl, C_{3-7} cycloalkyl or only one of the R_3 s and R_4 s is phenyl or substituted phenyl;

R_5 is hydrogen, tosylate, OT, C_{1-5} alkyl or C_{1-5} alkyl substituted with tosylate or OT, or C_{3-7} cycloalkyl or C_{3-7} cycloalkyl substituted with C_{1-7} alkyl, tosylate or OT, C_{2-5} alkenyl, phenyl or substituted phenyl in which the substituents are V and W, or R_5 is a group selected from:

a) C_{1-5} -alkanoyloxy- C_{1-4} -alkyl,


b)

$R_5-O-\overset{\overset{O}{\parallel}}{C}-(CH_2)_m$ in which m is 0 to 3 and R_6 is C_{1-5} alkyl;

c) $R_7R_8N-\overset{\overset{O}{\parallel}}{C}-(CH_2)_m$

in which R_7 and R_8 are independently C_{1-5} alkyl or R_7 and R_8 together with the nitrogen atom to which they are attached form a heterocycle selected from piperidiny, morpholiny, pyrrolidiny, piperaziny or thiomorpholiny;

d)




in which q is 0 to 2 and R_9 is C_{1-5} alkyl or phenyl or substituted phenyl in which the substituents are V and W;


V and W independently are hydrogen, halogen, hydroxy, trifluoromethyl, C_{1-3} alkyl, C_{1-3} alkyloxy and $TO-C_{1-3}$ alkyl;

T is tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl.


6. A compound of Claim 5 wherein:
 R₁ is methyl;
 R₂ is hydrogen or methyl;
 each of the R₃'s and R₄'s are independently hydrogen or C₁₋₃alkyl.
7. A compound of Claim 6 wherein:
 R₅ is hydrogen, tosylate, OT, C₁₋₅ alkyl, phenyl or substituted phenyl in which the substituents are V and W;
 T is tert-butyldimethylsilyl.
8. A compound of Claim 7 selected from the group wherein:
 a) n is 0, R₂ is methyl, R₅ is ethyl;
 b) n is 0, R₂ is hydrogen, R₅ is ethyl.
9. A process for the preparation of a compound of Claim 1 which comprises
 (a) treating a compound (1)




- with a hydroxyl protecting group compound selected from tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, trimethylsilyl chloride, triethylsilyl chloride, triisopropylsilyl chloride, or dihydropyran to yield a compound (2);




- (b) contacting a compound (2); with phenylselenenyl chloride or phenylselenenyl bromide (X = Cl or Br) at about -80° C in methylene chloride followed by treatment with 30% hydrogen peroxide in tetrahydrofuran at about 25° C to yield a compound (3); then




(c) treating compound (3) with a trialkyltin hydride or a triaryltin hydride and a radical initiator to yield a compound (4);




(d) contacting compound (4) with nitrosyl chloride and pyridine followed by irradiation with light of wave length greater than 320Å in benzene-pyridine to yield a compound (5);




(e) treating compound (5) with aqueous HF/CH₃CN at about -15° C to yield compound (6);




15 (f) heating compound (6) in isopropanol at about 95° C to afford compound (7);



30 (g) treating compound (7) with an aqueous paraformaldehyde solution in the presence of an acid catalyst to yield compound (8).



50 10. A process for the preparation of a compound of Claim 5 which comprises:
(h) contacting compound (8)



15 with aluminum isopropoxide and aluminum oxide in isopropanol to yield a compound (9).

